We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Transfusion Practice Wastes Scarce Plasma

By LabMedica International staff writers
Posted on 30 Jul 2013
The use of a blood transfusion protocol in patients with severe trauma is feasible in hospitals, although it is associated with higher waste of plasma.

The protocol, in use since 2007, uses an equal ratio of red blood cells, plasma, and platelets to transfuse patients, yet this 1:1:1 ratio is associated with higher waste of donated blood plasma.

Scientists at the Sunnybrook Health Sciences Center (Toronto, ON, Canada) conducted a randomized trial to determine feasibility and safety of 1:1:1 ratio in 78 patients presenting in a large trauma center, with low blood pressure and substantial bleeding who were expected to need massive blood transfusion. More...
Forty patients were randomly assigned to the fixed-ratio transfusion, and the remaining 38 underwent the laboratory-guided transfusion protocol at the center.

Thawed type AB plasma, a scarce resource, is needed for 1:1:1 transfusion, which also involves delays because of the need to thaw the material. Deaths from all causes after 28 days was higher in the fixed-ratio group at 32.5% compared with 14% in the control group and there was a higher rate of respiratory distress in the patients receiving 1:1:1.


Sandro Rizoli, MD, PhD, a professor of surgery and senior author of the study, said, “These findings suggest that a fixed-ratio transfusion protocol is feasible, but it was associated with increased plasma wastage, about two units per patient”. Widespread adoption of the 1:1:1 strategy has significant resource and safety implications. Its full implementation requires access to thawed type AB plasma, which is chronically in short supply. The 1:1:1 transfusion protocol may lead to unnecessary exposure to blood components and an increased risk of acute respiratory distress syndrome, sepsis, and multiple organ dysfunctions.

The authors concluded that the randomized controlled trial showed the implementation of a fixed-ratio (1:1:1) transfusion protocol was feasible among patients with severe trauma. The full and widespread implementation of such a protocol will challenge blood suppliers because of the increased demand and wastage of plasma. Larger clinical trials are warranted to definitively evaluate the efficacy and safety of transfusion at a 1:1:1 ratio. The study was published on July 15, 2013, in the Canadian Medical Association Journal.

Related Links:
Sunnybrook Health Sciences Center



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.